Substituted phenanthridinones and methods of use thereof

Details Substituted phenanthridinones and methods of use thereof Substituted phenanthridinones and methods of use thereof

2000-06-22

2002-11-05

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S319000, C514S331000, C514S298000, C546S141000, C546S146000, C546S143000, C546S108000

Reexamination Certificate

active

06476048

ABSTRACT:

BACKGROUND OF THE INVENTION
Inflammation disorders, such as arthritis, colitis, and autoimmune diabetes, typically manifest themselves as disorders distinct form those associated with reperfusion injury, e.g., stroke and heart attack, and can clinically manifest themselves as different entities. However, there can be common underlying mechanisms between these two types of disorders. In particular, inflammation and reperfusion injury can induce proinflammatory cytokine and chemokine synthesis. Induction of pro-inflammatory cytokines can, in turn, result in production of cytotoxic free radicals such as nitric oxide and superoxide. NO and superoxide can react to form peroxynitrite (ONOO
−
) (Szabó et al., Shock 6:79-88, 1996).
The peroxynitrite-induced cell necrosis observed in inflammation and reperfusion injury involves, in significant part, the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS). Activation of PARS is thought to be an important step in the cell-mediated death observed in inflammation and reperfusion injury (Szabó et al., Trends Pharmacol. Sci. 19: 287-98, 1998).
SUMMARY OF THE INVENTION
The invention is based in part on the discovery of novel substituted 6(5H)phenanthridinone derivatives and their unexpected effects in inhibiting inflammation, in treating reperfusion injuries, and in reducing the severity of diabetes.
Accordingly, in one aspect the invention provides novel substituted 6(5H)phenanthridinone derivatives falling within formula I, as set forth in the Detailed Description of the Invention, below.
Also provided is a method of treating inflammatory and reperfusion conditions in mammals by administering to a mammal in need of such treatment an effective amount of a compound according to formula I.
In a further aspect, the invention also includes a method for the production of compounds of formula I.
The substituted 6(5H)phenanthridinone compounds of the invention are potent, pharmaceutical compounds that can be used to treat a variety of conditions and diseases, typically those known to involve inflammatory mediator production and cell death.
The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference.


REFERENCES:
patent: 3291801 (1966-12-01), Montgomery
patent: 3932643 (1976-01-01), Gauthier
patent: 5519053 (1996-05-01), Kun et al.
patent: 5552267 (1996-09-01), Stern et al.
patent: 5583155 (1996-12-01), Kun et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5621104 (1997-04-01), Graham et al.
patent: 5908861 (1999-06-01), Kun
patent: 6121278 (2000-09-01), Jackson et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6235748 (2001-05-01), Li et al.
patent: 6291425 (2001-09-01), Li et al.
patent: 6346536 (2002-02-01), Li et al.
patent: 6348475 (2002-02-01), Zhang et al.
patent: 6358975 (2002-03-01), Eliasson et al.
patent: 2001/0020013 (2001-09-01), Zhang et al.
patent: 2002/0006927 (2002-01-01), Li et al.
patent: 2002/0019417 (2002-02-01), Zhang et al.
patent: 2002/0022636 (2002-02-01), Li et al.
patent: 2002/0028813 (2002-03-01), Jackson et al.
patent: 2002/0028815 (2002-03-01), Ator et al.
patent: 2002/0037904 (2002-03-01), Li et al.
patent: 0 638 309 (1995-02-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11622 (1999-03-01), None
patent: WO 99/11623 (1999-03-01), None
patent: WO 99/11624 (1999-03-01), None
patent: 9911624 (1999-03-01), None
patent: WO 99/11628 (1999-03-01), None
patent: WO 99/11644 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/36402 (1999-07-01), None
patent: WO 99/59973 (1999-11-01), None
patent: WO 99/59975 (1999-11-01), None
patent: WO 00/39070 (2000-07-01), None
patent: WO 00/39104 (2000-07-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 01/21615 (2001-03-01), None
Cookson M.R. et al., “J. Neurochem.” ;70/2,501-508(1998); Peroxynitrile & Hydrogen Peroxide . . . role of ADP-rib.*
Weltin et al., “Int'l J.Radiat.Biol.”;72/6,685-692(1997);Effect of 6(5H)-phenanthridinone-PARS.*
Banisk M. and Ueda K., Mole. Cell. Biochem. 138:185-197 (1994).
Griffin et al., J. Med. Chem. 41:5247-5256 (1998).
White et al., J. Med. Chem. 43:4084-4097 (2000).
Bowes et al. Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress.Cardiovasc Res.1999;41:126-134.
Cozzocrea et al. Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion.Br J Pharmacol.1997;121:1065-1074.
Docherty et al. An inhibitor of poly (ADP-ribse) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischemic rat heart.Br J Pharmacol.1999;127:1518-1524.
Grupp et al. Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts.J Mol Cell Cardiol.1999;31:297-303.
Szabo et al. Poly (ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation.Cir Res.2002;90:100-106.
Szabo et al. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment.J Exp Med.1997;186:1041-1049.
Thiemermann et al. Inhibition of the activity of poly (ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle.Proc Natl Acad Sci USA.1997;94:679-683.
Zingarelli et al. Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP ribose) synthetase.Cardiovasc Res.1997;36:205-215.
Andrievskii, et al., Chem. Heterocycl. Compds. (English Transl.), 21, 924-931 (1985).
Banasik, et al., J. Biol. Chem., 267, 1569-1575 (1991).
Migachev & Terent'ev, Chem. Heterocycl. Compds. (English Transl.), 17,394-397 (1981).
Nemeth, et al., Eur. J. Pharmacol, 339, 215-221 (1997).
Szabo, Shock, 6, 79-88 (1996).
Szabo & Dawson, Trends Pharmacol. Sci., 19, 287-298 (1998).
Taylor & Strojny, J. Am. Chem. Soc., 78, 5104-5108 (1956).
Virag and Szabo, Br. J. Pharmacol., 126, 769-777 (1999).
Crowley, et al., Journal of Pharmacology, 259:78-85 (1991).
Weltin, et al., International Journal of Radiation Biology, 72:685-692 (1997).

Affiliated with

Also associated with

Rating

Substituted phenanthridinones and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted phenanthridinones and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenanthridinones and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2924185